ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine Receptor D2 Antagonist  - 102191

Spotlight
Video

ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine Receptor D2 Antagonist 

Cancer-News has 111 videos Subscribe Here

Loading........
Description: Andrew Chi, MD, PhD at NYU Langone Medical Center explains how ONC201 has Selectivity Anti-Cancer Properties and is a Dopamine Receptor D2 Antagonist. Clinical Trial: ONC201 in Adults With Recurrent H3 K27M High-grade Glioma.
Shared By : Cancer-News
Posted on : 03/20/18
Added : 6 months ago
Category : Brain Cancer



Recommended

Nothing found.